Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 7813072, 8 pages
http://dx.doi.org/10.1155/2016/7813072
Review Article

Role of NADPH Oxidase in Metabolic Disease-Related Renal Injury: An Update

Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China

Received 2 June 2016; Accepted 17 July 2016

Academic Editor: Juan F. Santibanez

Copyright © 2016 Cheng Wan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Kassi, P. Pervanidou, G. Kaltsas, and G. Chrousos, “Metabolic syndrome: definitions and controversies,” BMC Medicine, vol. 9, article 48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. K. G. M. M. Alberti, P. Zimmet, and J. Shaw, “The metabolic syndrome—a new worldwide definition,” The Lancet, vol. 366, no. 9491, pp. 1059–1062, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Chen, P. Muntner, L. L. Hamm et al., “The metabolic syndrome and chronic kidney disease in U.S. Adults,” Annals of Internal Medicine, vol. 140, no. 3, pp. 167–174, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Kurella, J. C. Lo, and G. M. Chertow, “Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults,” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2134–2140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Chen, P. Muntner, L. L. Hamm et al., “Insulin resistance and risk of chronic kidney disease in nondiabetic US adults,” Journal of the American Society of Nephrology, vol. 14, no. 2, pp. 469–477, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Chen, D. Gu, C.-S. Chen et al., “Association between the metabolic syndrome and chronic kidney disease in Chinese adults,” Nephrology Dialysis Transplantation, vol. 22, no. 4, pp. 1100–1106, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. C. M. Hoehner, K. J. Greenlund, S. Rith-Najarian, M. L. Casper, and W. M. McClellan, “Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project,” Journal of the American Society of Nephrology, vol. 13, no. 6, pp. 1626–1634, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Nita and A. Grzybowski, “The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3164734, 23 pages, 2016. View at Publisher · View at Google Scholar
  9. Y. Gorin and K. Block, “Nox as a target for diabetic complications,” Clinical Science, vol. 125, no. 8, pp. 361–382, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. P. S. Gill and C. S. Wilcox, “NADPH oxidases in the kidney,” Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1597–1607, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Gorin and K. Block, “Nox4 and diabetic nephropathy: with a friend like this, who needs enemies?” Free Radical Biology and Medicine, vol. 61, pp. 130–142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Gorin, K. Block, J. Hernandez et al., “Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney,” Journal of Biological Chemistry, vol. 280, no. 47, pp. 39616–39626, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Gorin and F. Wauquier, “Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease,” Molecules and Cells, vol. 38, no. 4, pp. 285–296, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Bedard and K.-H. Krause, “The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology,” Physiological Reviews, vol. 87, no. 1, pp. 245–313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Panday, M. K. Sahoo, D. Osorio, and S. Batra, “NADPH oxidases: an overview from structure to innate immunity-associated pathologies,” Cellular and Molecular Immunology, vol. 12, no. 1, pp. 5–23, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Chen, X.-F. Meng, and C. Zhang, “Role of NADPH oxidase-mediated reactive oxygen species in podocyte injury,” BioMed Research International, vol. 2013, Article ID 839761, 7 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. S. A. Jones, J. T. Hancock, O. T. G. Jones, A. Neubauer, and N. Topley, “The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox,” Journal of the American Society of Nephrology, vol. 5, no. 7, pp. 1483–1491, 1995. View at Google Scholar · View at Scopus
  18. A. Whaley-Connell, J. Habibi, R. Nistala et al., “Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment,” Hypertension, vol. 51, no. 2, pp. 474–480, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. C. D. Bondi, N. Manickam, D. Y. Lee et al., “NAD(P)H oxidase mediates TGF-β1-induced activation of kidney myofibroblasts,” Journal of the American Society of Nephrology, vol. 21, no. 1, pp. 93–102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. A. Eid, Y. Gorin, B. M. Fagg et al., “Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases,” Diabetes, vol. 58, no. 5, pp. 1201–1211, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Wingler, S. Wünsch, R. Kreutz, L. Rothermund, M. Paul, and H. H. H. W. Schmidt, “Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo,” Free Radical Biology and Medicine, vol. 31, no. 11, pp. 1456–1464, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Block, A. Eid, K. K. Griendling, D.-Y. Lee, Y. Wittrant, and Y. Gorin, “Nox4 NAD(P)H oxidase mediates Src-dependent tyrosine phosphorylation of PDK-1 in response to angiotensin II: role in mesangial cell hypertrophy and fibronectin expression,” The Journal of Biological Chemistry, vol. 283, no. 35, pp. 24061–24076, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Meng, D.-D. Lv, and J. Fang, “Insulin-like growth factor-I induces reactive oxygen species production and cell migration through Nox4 and Rac1 in vascular smooth muscle cells,” Cardiovascular Research, vol. 80, no. 2, pp. 299–308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Miyata, M. Rahman, T. Shokoji et al., “Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells,” Journal of the American Society of Nephrology, vol. 16, no. 10, pp. 2906–2912, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J. L. Barnes and Y. Gorin, “Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases,” Kidney International, vol. 79, no. 9, pp. 944–956, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. F. A. Hakim and A. Pflueger, “Role of oxidative stress in diabetic kidney disease,” Medical Science Monitor, vol. 16, no. 2, pp. RA37–RA48, 2010. View at Google Scholar · View at Scopus
  27. D. K. Singh, P. Winocour, and K. Farrington, “Oxidative stress in early diabetic nephropathy: fueling the fire,” Nature Reviews Endocrinology, vol. 7, no. 3, pp. 176–184, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Asaba, A. Tojo, M. L. Onozato et al., “Effects of NADPH oxidase inhibitor in diabetic nephropathy,” Kidney International, vol. 67, no. 5, pp. 1890–1898, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. S. M. Nam, M. Y. Lee, J. H. Koh et al., “Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property,” Diabetes Research and Clinical Practice, vol. 83, no. 2, pp. 176–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Kitada, S. Kume, N. Imaizumi, and D. Koya, “Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1- independent pathway,” Diabetes, vol. 60, no. 2, pp. 634–643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Tojo, K. Asaba, and M. L. Onozato, “Suppressing renal NADPH oxidase to treat diabetic nephropathy,” Expert Opinion on Therapeutic Targets, vol. 11, no. 8, pp. 1011–1018, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Gorin, R. C. Cavaglieri, K. Khazim et al., “Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes,” American Journal of Physiology—Renal Physiology, vol. 308, no. 11, pp. F1276–F1287, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Fujii, T. Inoguchi, Y. Maeda et al., “Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice,” Kidney International, vol. 72, no. 4, pp. 473–480, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. S. J. Shankland, “The podocyte's response to injury: role in proteinuria and glomerulosclerosis,” Kidney International, vol. 69, no. 12, pp. 2131–2147, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. A. A. Eid, B. M. Ford, K. Block et al., “AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes,” The Journal of Biological Chemistry, vol. 285, no. 48, pp. 37503–37512, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. L. L. Zhou, F. F. Hou, G. B. Wang et al., “Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms,” Kidney International, vol. 76, no. 11, pp. 1148–1160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Susztak, A. C. Raff, M. Schiffer, and E. P. Böttinger, “Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy,” Diabetes, vol. 55, no. 1, pp. 225–233, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Xu, Z. Li, P. Xu, and Z. Yang, “Protective effects of leukemia inhibitory factor against oxidative stress during high glucose-induced apoptosis in podocytes,” Cell Stress and Chaperones, vol. 17, no. 4, pp. 485–493, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Toyonaga, K. Tsuruya, H. Ikeda et al., “Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production,” Nephrology Dialysis Transplantation, vol. 26, no. 8, pp. 2475–2484, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Papadimitriou, E. B. M. I. Peixoto, K. C. Silva, J. M. Lopes de Faria, and J. B. Lopes de Faria, “Increase in AMPK brought about by cocoa is renoprotective in experimental diabetes mellitus by reducing NOX4/TGFβ-1 signaling,” The Journal of Nutritional Biochemistry, vol. 25, no. 7, pp. 773–784, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Greiber, T. Münzel, S. Kästner, B. Müller, P. Schollmeyer, and H. Pavenstädt, “NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate,” Kidney International, vol. 53, no. 3, pp. 654–663, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Nistala, A. Whaley-Connell, and J. R. Sowers, “Redox control of renal function and hypertension,” Antioxidants & Redox Signaling, vol. 10, no. 12, pp. 2047–2089, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Etoh, T. Inoguchi, M. Kakimoto et al., “Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment,” Diabetologia, vol. 46, no. 10, pp. 1428–1437, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. S. Kanwar, L. Sun, P. Xie, F.-Y. Liu, and S. Chen, “A glimpse of various pathogenetic mechanisms of diabetic nephropathy,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 395–423, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Zhang, S. Pang, B. Deng et al., “High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-κB/NADPH oxidase/ROS pathway, which is inhibited by resveratrol,” The International Journal of Biochemistry & Cell Biology, vol. 44, no. 4, pp. 629–638, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Xia, H. Wang, H. J. Goldberg, S. Munk, I. G. Fantus, and C. I. Whiteside, “Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression,” American Journal of Physiology—Renal Physiology, vol. 290, no. 2, pp. F345–F356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Whiteside, H. Wang, L. Xia, S. Munk, H. J. Goldberg, and I. G. Fantus, “Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells,” Experimental Diabetes Research, vol. 2009, Article ID 910783, 11 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Maeda, T. Inoguchi, R. Takei et al., “Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters,” American Journal of Physiology—Renal Physiology, vol. 299, no. 6, pp. F1328–F1338, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. K. N. Campbell, L. Raij, and P. Mundel, “Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes,” Current Diabetes Reviews, vol. 7, no. 1, pp. 3–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Gorin, J. M. Ricono, N.-H. Kim, B. Bhandari, G. G. Choudhury, and H. E. Abboud, “Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells,” American Journal of Physiology—Renal Physiology, vol. 285, no. 2, pp. F219–F229, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. J. C. Jha, S. P. Gray, D. Barit et al., “Genetic targeting or pharmacologic inhibition of NADPH oxidase Nox4 provides renoprotection in long-term diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 25, no. 6, pp. 1237–1254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Gorin, J. M. Ricono, B. Wagner et al., “Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells,” The Biochemical Journal, vol. 381, part 1, pp. 231–239, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Yu, Y. Liu, Y. Wu et al., “Smad3/Nox4-mediated mitochondrial dysfunction plays a crucial role in puromycin aminonucleoside-induced podocyte damage,” Cellular Signalling, vol. 26, no. 12, pp. 2979–2991, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Das, S. Xu, X. Quan et al., “Upregulation of mitochondrial Nox4 mediates TGF-β-induced apoptosis in cultured mouse podocytes,” American Journal of Physiology—Renal Physiology, vol. 306, no. 2, pp. F155–F167, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. V. W. Dennis and K. Robinson, “Homocysteinemia and vascular disease in end-stage renal disease,” Kidney International, Supplement, vol. 50, no. 57, pp. S11–S17, 1996. View at Google Scholar · View at Scopus
  56. F. Yi and P.-L. Li, “Mechanisms of homocysteine-induced glomerular injury and sclerosis,” American Journal of Nephrology, vol. 28, no. 2, pp. 254–264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Gupta and K. Robinson, “Hyperhomocysteinaemia and end stage renal disease,” Journal of Nephrology, vol. 10, no. 2, pp. 77–84, 1997. View at Google Scholar · View at Scopus
  58. A. Erol, M. G. Çnar, C. Can, M. Olukman, S. Ülker, and S. Koşay, “Effect of homocysteine on nitric oxide production in coronary microvascular endothelial cells,” Endothelium: Journal of Endothelial Cell Research, vol. 14, no. 3, pp. 157–161, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Chow, F. Cheung, T. T. H. Lao, and O. Karmin, “Effect of homocysteine on the production of nitric oxide in endothelial cells,” Clinical and Experimental Pharmacology & Physiology, vol. 26, no. 10, pp. 817–818, 1999. View at Publisher · View at Google Scholar · View at Scopus
  60. X. Liu, F. Luo, J. Li, W. Wu, L. Li, and H. Chen, “Homocysteine induces connective tissue growth factor expression in vascular smooth muscle cells,” Journal of Thrombosis and Haemostasis, vol. 6, no. 1, pp. 184–192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Guo, J.-D. Lee, H. Uzui et al., “Effects of heparin on the production of homocysteine-induced extracellular matrix metalloproteinase-2 in cultured rat vascular smooth muscle cells,” The Canadian Journal of Cardiology, vol. 23, no. 4, pp. 275–280, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Yi, M. Xia, N. Li, C. Zhang, L. Tang, and P.-L. Li, “Contribution of guanine nucleotide exchange factor Vav2 to hyperhomocysteinemic glomerulosclerosis in rats,” Hypertension, vol. 53, no. 1, pp. 90–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Shastry, A. J. Ingram, J. W. Scholey, and L. R. James, “Homocysteine induces mesangial cell apoptosis via activation of p38-mitogen-activated protein kinase,” Kidney International, vol. 71, no. 4, pp. 304–311, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. F. Yi, A. Y. Zhang, N. Li et al., “Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats,” Kidney International, vol. 70, no. 1, pp. 88–96, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Pin-Lan, Y. Fan, and L. Ningjun, “Hyperhomocysteinemia: association with renal transsulfuration and redox signaling in rats,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 12, pp. 1688–1693, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Yi, E. A. Dos Santos, M. Xia, Q.-Z. Chen, P.-L. Li, and N. Li, “Podocyte injury and glomerulosclerosis in hyperhomocysteinemic rats,” American Journal of Nephrology, vol. 27, no. 3, pp. 262–268, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Zhang, J.-J. Hu, M. Xia et al., “Protection of podocytes from hyperhomocysteinemia-induced injury by deletion of the gp91phox gene,” Free Radical Biology & Medicine, vol. 48, no. 8, pp. 1109–1117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Zhang, J.-J. Hu, M. Xia, K. M. Boini, C. Brimson, and P.-L. Li, “Redox signaling via lipid raft clustering in homocysteine-induced injury of podocytes,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1803, no. 4, pp. 482–491, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Zhang, M. Xia, K. M. Boini et al., “Epithelial-to-mesenchymal transition in podocytes mediated by activation of NADPH oxidase in hyperhomocysteinemia,” Pflugers Archiv European Journal of Physiology, vol. 462, no. 3, pp. 455–467, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. C.-X. Li, M. Xia, W.-Q. Han et al., “Reversal by growth hormone of homocysteine-induced epithelial-to- mesenchymal transition through membrane raft-redox signaling in podocytes,” Cellular Physiology and Biochemistry, vol. 27, no. 6, pp. 691–702, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. J. M. Abais, C. Zhang, M. Xia et al., “NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia,” Antioxidants and Redox Signaling, vol. 18, no. 13, pp. 1537–1548, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. A. J. Ingram, J. C. Krepinsky, L. James et al., “Activation of mesangial cell MAPK in response to homocysteine,” Kidney International, vol. 66, no. 2, pp. 733–745, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. Z.-Z. Yang and A.-P. Zou, “Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells,” Kidney International, vol. 63, no. 3, pp. 1012–1020, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. F. Yi, A. Y. Zhang, J. L. Janscha, P.-L. Li, and A.-P. Zou, “Homocysteine activates NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells,” Kidney International, vol. 66, no. 5, pp. 1977–1987, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Zhang, F. M. Yi, M. Xia et al., “NMDA receptor-mediated activation of NADPH oxidase and glomerulosclerosis in hyperhomocysteinemic rats,” Antioxidants and Redox Signaling, vol. 13, no. 7, pp. 975–986, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. J. R. Diamond, “Hyperlipidemia of nephrosis: pathophysiologic role in progressive glomerular disease,” American Journal of Medicine, vol. 87, no. 5N, pp. 25N–29N, 1989. View at Google Scholar · View at Scopus
  77. S. Anderson, A. J. King, and B. M. Brenner, “Hyperlipidemia and glomerular sclerosis: an alternative viewpoint,” The American Journal of Medicine, vol. 87, no. 5, pp. 34N–38N, 1989. View at Google Scholar · View at Scopus
  78. V. S. Kamanna, D. D. Roh, and M. A. Kirschenbaum, “Hyperlipidemia and kidney disease: concepts derived from histopathology and cell biology of the glomerulus,” Histology and Histopathology, vol. 13, no. 1, pp. 169–179, 1998. View at Google Scholar
  79. W. F. Keane, M. P. O'Donnell, B. L. Kasiske, and P. G. Schmitz, “Lipids and the progression of renal disease,” Journal of the American Society of Nephrology, vol. 1, no. 5, pp. S69–S74, 1990. View at Google Scholar · View at Scopus
  80. J. A. Joles, U. Kunter, U. Janssen et al., “Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats,” Journal of the American Society of Nephrology, vol. 11, no. 4, pp. 669–683, 2000. View at Google Scholar · View at Scopus
  81. B. L. Kasiske, M. P. O'Donnell, W. J. Garvis, and W. F. Keane, “Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure,” Circulation Research, vol. 62, no. 2, pp. 367–374, 1988. View at Publisher · View at Google Scholar · View at Scopus
  82. K.-P. Shen, H.-L. Lin, W.-T. Chang et al., “Eugenosedin-A ameliorates hyperlipidemia-induced vascular endothelial dysfunction via inhibition of α1-adrenoceptor/5-HT activity and NADPH oxidase expression,” Kaohsiung Journal of Medical Sciences, vol. 30, no. 3, pp. 116–124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Scheuer, W. Gwinner, J. Hohbach et al., “Oxidant stress in hyperlipidemia-induced renal damage,” American Journal of Physiology-Renal Physiology, vol. 278, no. 1, pp. F63–F74, 2000. View at Google Scholar · View at Scopus
  84. L. He, L. Hao, X. Fu, M. Huang, and R. Li, “Severe hypertriglyceridemia and hypercholesterolemia accelerating renal injury: a novel model of type 1 diabetic hamsters induced by short-term high-fat / high-cholesterol diet and low-dose streptozotocin,” BMC Nephrology, vol. 16, article 51, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. J. P. Tolins, B. G. Stone, and L. Raij, “Interactions of hypercholesterolemia and hypertension in initiation of glomerular injury,” Kidney International, vol. 41, no. 5, pp. 1254–1261, 1992. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Oda, Y. Satta, O. Takenaka, and N. Takahata, “Loss of urate oxidase activity in hominoids and its evolutionary implications,” Molecular Biology and Evolution, vol. 19, no. 5, pp. 640–653, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. O. S. P. Sah and Y. X. Qing, “Associations between hyperuricemia and chronic kidney disease: a review,” Nephro-Urology Monthly, vol. 7, no. 3, Article ID e27233, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. G. K. Glantzounis, E. C. Tsimoyiannis, A. M. Kappas, and D. A. Galaris, “Uric acid and oxidative stress,” Current Pharmaceutical Design, vol. 11, no. 32, pp. 4145–4151, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. R. J. Johnson, D.-H. Kang, D. Feig et al., “Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?” Hypertension, vol. 41, no. 6, pp. 1183–1190, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. L. Li, C. Yang, Y. Zhao, X. Zeng, F. Liu, and P. Fu, “Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies,” BMC Nephrology, vol. 15, no. 1, article 122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Stack, A. J. Manolis, and E. Ritz, “Detrimental role of hyperuricemia on the cardio-reno-vascular system,” Current Medical Research and Opinion, vol. 31, supplement 2, pp. 21–26, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. D.-H. Kang and T. Nakagawa, “Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease,” Seminars in Nephrology, vol. 25, no. 1, pp. 43–49, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. P. Dousdampanis, K. Trigka, C. G. Musso, and C. Fourtounas, “Hyperuricemia and chronic kidney disease: an enigma yet to be solved,” Renal Failure, vol. 36, no. 9, pp. 1351–1359, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. N. Ohashi, S. Ishigaki, S. Isobe et al., “Hyperuricaemia is associated with renal damage independently of hypertension and intrarenal renin-angiotensin system activation, as well as their circadian rhythms,” Nephrology, vol. 20, no. 11, pp. 814–819, 2015. View at Publisher · View at Google Scholar · View at Scopus
  95. W.-J. Ho, W.-P. Tsai, K.-H. Yu et al., “Association between endothelial dysfunction and hyperuricaemia,” Rheumatology, vol. 49, no. 10, pp. 1929–1934, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. M.-A. Yu, L. G. Sánchez-Lozada, R. J. Johnson, and D.-H. Kang, “Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction,” Journal of Hypertension, vol. 28, no. 6, pp. 1234–1242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. L. G. Sánchez-Lozada, V. Soto, E. Tapia et al., “Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia,” American Journal of Physiology—Renal Physiology, vol. 295, no. 4, pp. F1134–F1141, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. D.-H. Kang and S.-K. Ha, “Uric acid puzzle: dual role as anti-oxidantand pro-oxidant,” Electrolyte & Blood Pressure, vol. 12, no. 1, pp. 1–6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. L. G. Sánchez-Lozada, M. A. Lanaspa, M. Cristóbal-García et al., “Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations,” Nephron - Experimental Nephrology, vol. 121, no. 3-4, pp. e71–e78, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. E.-S. Ryu, M. J. Kim, H.-S. Shin et al., “Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease,” American Journal of Physiology—Renal Physiology, vol. 304, no. 5, pp. F471–F480, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. J. E. Quigley, A. A. Elmarakby, S. F. Knight et al., “Obesity induced renal oxidative stress contributes to renal injury in salt-sensitive hypertension,” Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 7, pp. 724–728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Darouich, R. Goucha, M. H. Jaafoura, S. Zekri, H. B. Maiz, and A. Kheder, “Clinicopathological characteristics of obesity-associated focal segmental glomerulosclerosis,” Ultrastructural Pathology, vol. 35, no. 4, pp. 176–182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. J. Habibi, M. R. Hayden, J. R. Sowers et al., “Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats,” Endocrinology, vol. 152, no. 2, pp. 659–668, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. H. Cai and D. G. Harrison, “Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress,” Circulation Research, vol. 87, no. 10, pp. 840–844, 2000. View at Google Scholar · View at Scopus
  105. L. M. Yung, F. P. Leung, X. Yao, Z.-Y. Chen, and Y. Huang, “Reactive oxygen species in vascular wall,” Cardiovascular and Hematological Disorders-Drug Targets, vol. 6, no. 1, pp. 1–19, 2006. View at Publisher · View at Google Scholar · View at Scopus